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Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) directly influence thrombus formation and degradation and
thereby risk for arterial thrombosis. Activation of the renin-angiotensin system has been linked to the production of PAI-1 expression via the
angiotensin II type 1 receptor (AT1R). In addition, bradykinin can induce the release of t-PA through a B2 receptor mechanism. In the present
study, we aimed to investigate the epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on
plasma t-PA and PAI-1 levels in a large population-based sample (n=2527). We demonstrated a strong significant interaction within genetic
variations of the bradykinin B2 gene (P=0.002) and between ACE and bradykinin B2 (p=0.003) polymorphisms on t-PA levels in females. In
males, polymorphisms in the bradykinin B2 and AT1R gene showed the most strong effect on t-PA levels (P=0.006). In both females and males,
the bradykinin B2 gene interacted with AT1R gene on plasma PAI-1 levels (P=0.026 and P=0.039, respectively). In addition, the current study
found a borderline significant interaction between PAI 4G5G and ACE I/D on plasma t-PA and PAI-1 levels. These results support the idea that the
interplay between the renin-angiotensin, bradykinin, and fibrinolytic systems might play an important role in t-PA and PAI-1 biology.
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process resulting in the hydrolytic cleavage of fibrin by plasmin
to promote clot dissolution and generate fibrin degradation
products. This system helps protect the circulation from
intravascular fibrin formation and thrombosis that would
otherwise lead to vessel occlusion and tissue ischemia [1,2].
The efficacy of plasminogen activation and fibrin degradation is
largely determined by the balance between local concentrations
of tissue-type plasminogen activator (t-PA) and its cognate⁎ Corresponding author. Computational Genetics Laboratory, 706 Rubin,
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doi:10.1016/j.ygeno.2006.11.004inhibitor, plasminogen activator inhibitor type 1 (PAI-1). There
is substantial evidence indicating that plasma t-PA and PAI-1 are
regulated in part by the renin-angiotensin system (RAS) [3].
Angiotensin II promotes the synthesis of PAI-1 in vitro [4,5].
Furthermore, ACE inhibitors have been shown to reduce plasma
PAI-1 levels in patients with postmyocardial infarction [6], in
hypertensive subjects [7], and in postmenopausal females [8].
Conversely, bradykinin is a potent stimulator for t-PA in humans
[9] and ACE inhibition augments bradykinin-induced t-PA
release from the arterial vasculature [10,11].
Interactions between the RAS, bradykinin, and fibrinolytic
systems on t-PA and PAI-1 levels may explain at least part of the
relationship between those systems and cardiovascular disease
and the beneficial effects of ACE inhibition on thrombotic
363F.W. Asselbergs et al. / Genomics 89 (2007) 362–369events. Indeed, prior studies demonstrated interactions between
genes from the fibrinolytic system and RAS on levels of t-PA
and PAI-1 [12–14]. However, these studies either were
performed in selected high-risk populations or had small
sample sizes. In addition, no study has yet investigated the
interplay between genes from the RAS, bradykinin, and
fibrinolytic systems on plasma levels of t-PA and PAI-1 in a
single study.
Therefore, the aim of the present study was to investigate the
effects of polymorphisms in genes from the renin-angiotensin,
bradykinin, and fibrinolytic systems on plasma levels of t-PA and
PAI-1 in a large population-based sample, explicitly examining
two-way epistatic interactions.
Results
Clinical characteristics of both females and males are listed
in Table 1. Except for body mass index and total cholesterol
levels, all characteristics are significantly different between
females and males.
Figs. 1 and 2 summarize the results of the statistical tests for
epistasis in the form of network diagrams for females and males,
respectively. Only significant results with suggestive or strong
evidence for interaction are illustrated. Supplementary Tables 1
and 2 present the P values for all statistical tests performed.
In females, we found significant evidence for fibrinolytic-
RAS, fibrinolytic-bradykinin, RAS-bradykinin, and bradykinin-
bradykinin interaction effects on plasma t-PA levels. A total of 7
gene-gene interactions were detected out of the 15 comparisons.
We also found significant evidence for fibrinolytic-RAS,
fibrinolytic-bradykinin, and RAS-bradykinin interaction effects
on plasma PAI-1 levels. A total of 6 gene-gene interactions were
detected out of the 15 comparisons.
In males, we found significant evidence for fibrinolytic-
RAS, RAS-bradykinin, RAS-RAS, and bradykinin-bradykinin
interaction effects on plasma t-PA levels. A total of 6 gene-gene
interactions were detected out of the 15 comparisons. We alsoTable 1







Age (years) 48±12 50±12 0.008
Body mass index (kg/m2) 25.8±4.5 25.9±3.4 0.447
Waist–hip ratio 0.82±0.07 0.93±0.07 <0.001
Current smoking 32.2% 37.0% 0.011
Diabetes 2.7% 3.2% 0.453
Systolic blood pressure (mm Hg) 122±19 131±17 <0.001
Diastolic blood pressure (mm Hg) 70±9 76±9 <0.001
Total cholesterol (mmol/L) 5.60±1.10 5.67±1.17 0.071
HDL-cholesterol (mmol/L) 1.52±40 1.18±0.32 <0.001
ln tissue type plasminogen activator
(ng/ml)
1.13±0.71 1.32±0.80 <0.001
ln plasminogen activator inhibitor 1
(ng/ml)
4.13±0.82 4.37±0.79 <0.001
⁎ P value calculated with student's t test for continuous variables and χ2 test
for categorical variables.found significant evidence for fibrinolytic-RAS, fibrinolytic-
bradykinin, RAS-bradykinin, and bradykinin-bradykinin inter-
action effects on plasma PAI-1 levels. A total of 7 gene-gene
interactions were detected out of the 15 comparisons.
Common to both traits and both genders were significant
interactions between genes from the bradykinin system and the
RAS, but the specific interaction detected differed between
gender. Fig. 3 illustrates the mean ln t-PA and mean ln PAI-1
levels by genotype combination in females and males. In each
case, there is evidence for crossing of the lines that is cha-
racteristic of epistasis. That is, the effect of any one poly-
morphism on either t-PA or PAI-1 levels is dependent on the
genotypes at the second polymorphism.
Thus, for both traits and both genders we found evidence
for multiple epistatic effects using either suggestive or strong
supporting statistical evidence. A total of 24 significant gene-
gene interactions were observed out of 60 possible. Of the 24,
10 involved dominant-recessive interactions, 7 involved rece-
ssive-recessive interactions, 4 involved dominant-additive
interactions, 2 involved recessive-additive interactions, and 1
involved a dominant-dominant interaction. It is important to
note that the interactions reported here and summarized in
Figs. 1 and 2 are only the most significant of those examined;
all results are shown in Supplementary Tables 1 and 2. For
example, the BDKRB2 C58T by ACE I/D interaction on t-PA
levels in females reported in Figs. 1 and 3 involved a
dominant by additive effect with a P value of 0.003. How-
ever, the additive by dominant (P=0.025), dominant by
dominant (P=0.007), and additive by additive (P=0.018)
were all statistically significant at an α=0.025 level. The
magnitude of each interaction effect was on the order of 1%
variation explained. This is consistent with a genetic architec-
ture in which many polymorphisms account for the heritability
of the trait. As such, it will be important to explore higher-order
models.
It is important to note that there are many differences between
females and males (see Figs. 1 and 2). For example, there was
strong evidence for an interaction effect of the BDKRB2 exon 1
I/D and BDKRB2 C181T polymorphisms on t-PA levels in
females (P=0.002) but not in males (P>0.10). As an additional
example, we observed strong evidence for an interaction effect
of the PAI-1 4G/5G and BDKRB2 C181T polymorphisms on
PAI-1 levels in males (P=0.023) but not in females (P>0.10).
These results are consistent with the gender-specific univariate
effects of these polymorphisms [31]. One similarity in females
and males is that in subjects homozygous for AT1R A1166C,
PAI-1 levels are lower in subjects heterozygous for BDKRB2
C58T in both females and males (Fig. 3).
Discussion
The present study examined the relationships between
genetic polymorphisms in the RAS, bradykinin, and fibrinolytic
systems on plasma levels of t-PA and PAI-1 in a large
population-based sample. We observed interactions between
genetic polymorphisms of the three different systems both on
plasma t-PA levels and on plasma PAI-1 levels. Interestingly,
Fig. 1. Polymorphisms of the renin-angiotensin, bradykinin, and fibrinolytic system show significant interactions on plasma t-PA and PAI-1 levels among females. Only the significant (P<0.025) and borderline
significant (P<0.10) interactions are presented. The lines illustrate the interactions between genes and line thickness is inversely related to the significance level. The model of inheritance is given in parentheses. A,















Fig. 2. Polymorphisms of the renin-angiotensin, bradykinin, and fibrinolytic system show significant interactions on plasma t-PA and PAI-1 levels among males. Only the significant (P<0.025) and borderline significant
(P<0.10) interactions are presented. The lines illustrate the interactions between genes and line thickness is inversely related to the significance level. The model of inheritance is given in parentheses. A, additive;















Fig. 3. A consistent significant interaction is present between polymorphisms of
the renin-angiotensin and bradykinin genes on plasma t-PA and PAI-1 levels
among females and males. The four panels illustrate the interactions on the
absolute values of the natural log-transformed t-PA and PAI-1. The genotypes
shown correspond to the BDKRB2 C58T (CC, TC, TT) in females for t-PA and
PAI-1 and males for PAI-1, BDKRB2 C181T (CC, TC, TT) in males for t-PA,
ACE I/D (II, ID, DD) in females for t-PA, and AT1R A116C (AA, AC, CC) in
females for PAI-1 and males for t-PA and PAI-1.
366 F.W. Asselbergs et al. / Genomics 89 (2007) 362–369these interactions appear to be different among females and
males.
Epistatic effects of RAS and bradykinin systems on plasma t-PA
and PAI-1 levels
The effect of RAS polymorphisms on t-PA and PAI-1 levels
has been studied previously, but no data are available about the
joint effects of RAS and bradykinin gene polymorphisms on
markers of the fibrinolytic system. The I/D polymorphism of
the ACE gene has been associated with PAI-1 levels in
apparently healthy persons [13], in patients with hypertension
[15], and in patients attending a metabolic ward [14]. In
contrast, no relation between ACE I/D polymorphism on PAI-1
levels could be detected in the National Heart, Lung, and Blood
Institute Family Heart Study [16]. In vitro data have shown that
the angiotensin II-induced PAI-1 expression may be mediated
by the angiotensin II type 1 receptor [3,17].
In the present study, polymorphisms of the RAS and brady-
kinin genes showed epistatic effects on both PAI-1 as t-PA levels
among females and males. In contrast to the aforementioned
relation between RAS gene polymorphisms and the fibrinolytic
system, less is known about the relation between bradykinin
gene polymorphisms and t-PA and PAI-1 levels. In addition to
being an inflammatory mediator, bradykinin is a potent
endothelial cell stimulant that can induce the acute release of t-
PA from the endothelium through a B2 receptor mechanism [18].
ACE inhibition augments the effects of bradykinin on the B2receptor, which leads to t-PA release from the endothelium [10].
In addition, a recent study showed that ACE inhibition reduced
PAI-1 expression in tubular epithelial cells by bradykinin action
[19]. To our knowledge, no study investigated the effect of
bradykinin gene polymorphisms or the interaction between RAS
and bradykinin gene polymorphisms on t-PA and PAI-1 levels.
In the present study, we demonstrate several significant
interactions between genetic variations of the bradykinin B2
gene on t-PA levels. These findings confirm results from prior
studies that bradykinin plays an important role on t-PA levels. In
addition, a consistent interaction was present between the RAS
and bradykinin systems on plasma levels of t-PA and PAI-1 in
both genders, although the nature of the interactions differed.
Epistatic effects of PAI 4G5G on plasma t-PA and PAI-1 levels
Despite the strong univariate relation between the PAI 4G5G
polymorphism and PAI levels [20], the PAI 4G/5G polymor-
phism did not interact very strongly with the RAS and brady-
kinin gene polymorphisms. However, a consistent interaction
was present between the PAI 4G5G and the ACE I/D poly-
morphisms in both females and males. This epistatic effect
between both systems has been described previously in patients
attending a metabolic ward [14] and a normotensive unrelated
population [21]. Angiotensin II may regulate PAI-1 levels in the
general population and inhibition of renin-angiotensin system
has been shown to reduce PAI-1 levels [8]. These data and the
current results support the idea that the two systems interact.
This therefore could potentially explain the beneficial effects of
ACE inhibition on thrombotic events.
Gender differences in epistatic effects on t-PA/PAI-1 levels
It is well known that risk for cardiovascular disease differs
among gender and several mechanisms have been proposed to
account for this difference [22]. One of the main mechanisms
might be the gender difference in fibrinolysis and thereby
thrombotic state. The THROMBO investigators found gender
differences in several thrombogenic factors predicting recurrent
cardiac events in patients after acute myocardial infarction [23].
Several study groups have postulated that the cardioprotective
effect of estrogen may be mediated, in part, by an increase in
fibrinolytic potential. Subjects with lower estrogen have a lower
fibrinolytic potential (higher PAI-1 levels) than subjects with a
high estrogen status [24]. This relation between estrogen and
fibrinolysis has been related to the capacity of estrogen to
regulate the RAS system [25,26]. In addition, ACE inhibition
therapy has been shown to increase basal t-PA release in females
but not in males [11]. Furthermore, side effects associated with
ACE inhibition such as coughing occur more frequently in
females than in males. The mechanism of cough associated with
ACE inhibitor therapy is related to the bradykinin metabolism,
which again is related to t-PA release in humans [27,28]. These
studies and the current results suggest sex-specific differences
in epistatic effects of RAS, bradykinin, and fibrinolytic system
on plasma t-PA and PAI-1 levels. Future studies are needed to
investigate whether gender-specific therapeutics need to be
367F.W. Asselbergs et al. / Genomics 89 (2007) 362–369developed protect against disease processes that show clear sex
difference in their etiology and progression.
Future considerations
This study supports the idea that epistasis is a ubiquitous
component of the genetic architecture of human traits [29].
Future studies need to address several issues to understand the
complicated epistatic effects of polymorphisms in the RAS,
bradykinin, and fibrinolytic genes. First, the nature and
biological interpretation of the interactions need to be
determined. Although this is very important, traversing the
hierarchical divide between statistical epistasis, observed as
deviations from additivity in a linear model that summarizes
specific patterns of genotypes and phenotypes across multiple
individuals in a sample, and biological epistasis, observed as
biomolecular interactions at the cellular level in an individual, is
very difficult and will likely only be possible when all
etiological factors can be measured [30,31]. Second, in addition
to the described systems, future studies need to consider other
systems that might be implicated in arterial thrombosis. Third,
this paper focused on two-way interactions, but high-order
interactions are certainly possible, but may be hard to detect due
to limits of the traditional statistical approaches [32]. Finally, we
need to consider the context of the environment on the genetic
effects (gene-environment interactions). This approach will lead
to a better understanding of the genetic architecture of
fibrinolytic factors and subsequently of the development of
arterial thrombosis in human.
In conclusion, the results of this large population-based study
support the idea that the interplay between the renin-
angiotensin, bradykinin, and fibrinolytic systems might have
an important role in t-PA and PAI-1 biology and thereby arterial
thrombosis.Materials and methods
Study population
The sample analyzed in this study was obtained from the ongoing
prospective Prevention of Renal and Vascular End-Stage Disease (PREVEND)
study. The PREVEND study was designed to investigate prospectively the
natural course of albuminuria and its relation to renal and cardiovascular
disease in a large cohort drawn from the general population. Details of the study
protocol have been described previously [33,34]. In summary, during 1997–
1998, all 85,421 inhabitants of the city of Groningen, the Netherlands, from the
ages of 28 to 75 years old, were sent a one-page postal questionnaire (regarding
demographics, use of medication, and pregnancy) and a vial to collect an early
morning urine sample. A total of 40,856 subjects responded. After exclusion of
subjects with type 1 diabetes mellitus, females who were possibly pregnant, and
males and females not able or willing to participate, a total of 6000 subjects with
a urinary albumin concentration≥10 mg l−1 and a random control sample of
subjects with a urinary albumin concentration<10 mg l−1 (n=2592) completed
the screening protocol and formed the baseline PREVEND cohort (n=8592).
From this cohort, we selected a random sample of 2527 subjects (1338 females
and 1189 males) as being representative of the entire population from which the
PREVEND cohort was selected. These individuals were used in the present
study to explore t-PA and PAI-1 levels in the general population. In this group,
t-PA and PAI-1 levels were missing in 39 (1.5%) and 42 (1.7%) subjects,
respectively. The PREVEND study was approved by the local medical ethicscommittee and conducted in accordance with the guidelines of the Declaration
of Helsinki.
Laboratory measurements
Blood samples were obtained during the morning in all subjects to minimize
variability due to circadian rhythms, but day-to-day variability of t-PA and PAI-1
levels was not addressed in the current study. Plasma levels of t-PA and PAI-1
were measured using an ELISA kit from Technoclone Gmbh (Vienna, Austria).
The assays measured both free t-PA and PAI-1 and their complexes. In brief,
diluted plasma samples were added to a 96-well microtiter plate coated with
antibodies to either t-PA or PAI and incubated for 2 h at 37°C. After being
washed, a peroxidase-labeled second antibody to either t-PA or PAI-1 was added
to the wells and the plate was incubated for 1 h at 37°C. After washing, substrate
(ABTS) was added. The reaction was stopped after 30 min and the absorbance at
405 nm was measured. Each assay included calibrants (1.0–20 ng/ml for t-PA
and 1.0–25 ng/ml for PAI-1) and two quality control samples. The lower limit of
quantification was 1.0 ng/ml for t-PA and 1.5 ng/ml for PAI-1. Assays not
meeting quality control standards were not included in the analyses.
Serum cholesterol was determined by Kodak Ektachem dry chemistry
(Eastman Kodak, Rochester, NY, USA). HDL-cholesterol was measured with a
homogeneous method (direct HDL, No. 7D67, AEROSET System; Abbott
Laboratories).
Measurement of genetic polymorphisms
The AT1R A1166C (rs5186), the BDKRB2 C-58T (rs1799722) and C181T
(rs1046248), and PAI 4G/5G (rs1799768) polymorphisms were analyzed using
TaqMan-MGB probes and PCR primers, designed through the Assay-by-Design
service (Applied Biosystems). TaqMan assays were carried out according to the
manufacturer’s recommendations on an ABI 7900HTapparatus and results were
analyzed with SDS 2.0 genotype calling software (Applied Biosystems).
The ACE I/D (rs4646994) and the BDKRB2 exon 1 insertion/deletion
polymorphisms were also analyzed by PCR amplification, with one of the
primers having a fluorescent label, and subsequent determination of the lengths
of the PCR products on a capillary sequencer. Primers were pickedwith the aid of
the online Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/pri-
mer3_www.cgi). After PCR cycling, samples of the above assays were pooled
and separated on a MegaBACE 1000 sequencer. Fragments were analyzed with
Genetic Profiler 2.0 software (Amersham Biosciences).
Statistical analysis
Continuous data are reported as means±standard deviation. Categorical data
are presented as per group percentages. Differences in continuous characteristics
between genders were evaluated by Student's t test. Differences in categorical
data between genders were compared with the χ2 test.
The primary goal of the statistical analysis was to test the null hypothesis that
the effect of any one polymorphism on t-PA or PAI-1 levels is not dependent on
one of the other polymorphisms. We used a two-way analysis of variance
(ANOVA) to test this null hypothesis. A statistically significant interaction term
was considered evidence in favor of the alternative hypothesis of epistasis or
gene-gene interaction. All tests were carried out in females and males separately
since the distributions of t-PA or PAI-1 have previously been shown to be gender
specific [34].
All genotypes were coded (AA=0, Aa=1, aa=2) to capture additive effects
(0=AA or Aa, 1=aa), to capture dominant effects and (0=AA, 1=Aa or aa), and
to capture recessive effects. All possible pairs of genotypes were evaluated using
ANOVA. The nine possible interaction effects tested included additive by
additive, additive by dominant, additive by recessive, dominant by additive,
dominant by dominant, dominant by recessive, recessive by additive, recessive
by dominant, and recessive by recessive. For each pair of polymorphisms, all
nine interactions were tested and the most significant result was reported. We did
not limit the analysis by eliminating rare genotypes since the sample size was
sufficient in most cases to estimate the interaction effects.
Within each gender and for each trait, we tested 15 possible pairs of
polymorphisms for epistatic effects.Within each of the 15 comparisons we tested
368 F.W. Asselbergs et al. / Genomics 89 (2007) 362–369the 9 possible interactions (e.g., additive by additive). Thus, there are multiple
statistical tests at the polymorphism level (15 tests) and at the genotype coding
level (9 tests). We present and use here two different levels of statistical
significance for making inferences about the epistatic effects of the polymorph-
isms studied. First, we used an uncorrected significance level of α=0.10 as
suggestive evidence for interaction. This liberal significance was selected for
several reasons. First, the pathways, genes, and polymorphisms selected for study
are all strong candidates for influencing t-PA and PAI-1 biochemistry. Second,
we used a more conservative significance level of α=0.025 as strong evidence
for interaction. This more conservative significance level was derived from 1000
Monte Carlo simulations under the null hypothesis. For each of the 1000
simulations, we recorded the smallest P values selected from the 9 different
interaction tests. From this null distribution we determined that a minimum P
value of approximately 0.025 or smaller was expected 10% of the time. All P
values for all tests performed are reported so the reader may make their own
interpretations regarding biological significance. We did not perform corrections
for multiple testing because the universal null hypothesis that is assumed for a
Bonferroni-type correction does not apply to this study [35]. In addition, this is
the first study to examine interactions among genes from the fibrinolytic, RAS,
and bradykinin systems. As such, we are more concerned about type II errors
(false-negatives) than type I errors (false-positives). This is especially true since
ANOVA has less power to detect interactions than independent main effects.Acknowledgments
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